Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "brensocatib"

2 News Found

Insmed’s Brensocatib fails to hit endpoints in hidradenitis suppurativa study
News | April 09, 2026

Insmed’s Brensocatib fails to hit endpoints in hidradenitis suppurativa study

The results were consistent across both the 10 mg and 40 mg treatment arms

UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
News | February 25, 2026

UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis

NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production

Latest Stories

Orbicular, Apotex win tentative USFDA nod for generic Ozempic

ISDE India Edition 2026 spotlights minimally invasive therapies for esophageal cancer

Mumbai’s Apex Hospital achieves landmark 607 knee replacement surgeries in FY26

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging